INBX Stock — Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. (INBX)

Updated October 16, 2026.

INBX is a Stock. Total return is 670.6% over the past 2.4 years, 621.2 points ahead of SPY at 49.4%.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic therapeutics for life-threatening conditions, with therapeutic candidates in early-stage trials targeting cancers and solid tumors. As an early-stage biotech company, it does not currently distribute dividends. This security is oriented toward investors with high risk tolerance who are willing to accept significant uncertainty in pursuit of potential long-term capital appreciation in the biotechnology sector.

INBX performance versus SPY

Price and return data through 2026-10-16.

Total return is 670.6% over the past 2.4 years, 621.2 points ahead of SPY at 49.4%. Over the past year its total return — price change plus distributions reinvested — is 145.5%. Its deepest 1-year drawdown was 44.1%.

INBX key facts

Asset type

Stock

Asset class

Equity

Inception date

05/29/2024

Distribution frequency

None

Last close

$89.83 (as of 2026-10-16)

Market cap

$1,322,087,398

Average volume

145923.0

Ex-dividend date

05/30/2024

Payment date

06/20/2024

Beta

3.822

Payout ratio

0.0%

EPS

$-8.88

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

INBX risks and drawbacks

The deepest 1-year drawdown on record here is 44.1%.

Who may consider INBX — and who may not

It is a weaker fit for investors who need monthly cash flow (INBX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on INBX

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions